Episode 7 looks outside severe asthma to borrow what works in oncology, migraine, and rare disease—and translate those access innovations to Lumara’s launch.

Episode 5 examines how real-world evidence (RWE) is now the currency of access decisions. Beyond trials, payers want proof in routine care—on exacerbations, persistence, and healthcare utilization—and they use it for formulary positioning and renewal negotiations.

Turning Up the Volume: How AI Voice Technology Reshaped Publishing—and What It Means for Other Industries Artificial intelligence is now...